Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Audentes Therapeutics (BOLD) and Novavax (NVAX).
Audentes Therapeutics (BOLD)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics today and set a price target of $33. The company’s shares closed yesterday at $27.77.
Chattopadhyay observed:
“While our Buy rating and $33 price target on shares of Audentes are unchanged, they are now leveraged solely on AT132. We have removed AT342 from our estimates pending clinical clarity anticipated during the company’s 1Q19 call estimated in May 2019. Given the robustness of the clinical data thus far, and the rarity of the condition, we are increasing our AT132 launch price to $1.7M vs. our prior estimate of $1M, which drives AT132 NPV to $33/share, vs. our prior $17/share.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.8% and a 49.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Audentes Therapeutics with a $37.67 average price target, a 35.6% upside from current levels. In a report issued on February 24, Chardan Capital also upgraded the stock to Buy with a $40 price target.
See today’s analyst top recommended stocks >>
Novavax (NVAX)
Cantor Fitzgerald analyst Matthew Lillis maintained a Hold rating on Novavax today and set a price target of $2. The company’s shares closed yesterday at $2.13.
Lillis observed:
“Our Neutral rating for NVAX stock is based on the uncertainty as to how the company’s technologies will be applied in the successful development of proprietary vaccines and where or how NVAX will access the capital necessary to realize that potential. Positive data for vaccine candidates would be a catalyst for share price appreciation, in our view. Valuation Summary We estimate the aggregate technical value of the programs to be higher than the current market price (probability-weighted $2-$6/share by our estimates).”
According to TipRanks.com, Lillis is a 3-star analyst with an average return of 10.3% and a 71.4% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Supernus Pharmaceuticals, and Evofem Biosciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novavax with a $3.88 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
